PASSAGE BIO, INC. Retained Earnings
PASSAGE BIO, INC. (PASG) had Retained Earnings of -$720.14 million as of 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-09-03
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$720.14M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$712.32M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$704.76M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$691.77M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$720.14M S-4/A · filed 2026-09-03 |
| 2026-03-31 | -$712.32M S-4 · filed 2026-07-21 |
| 2025-12-31 | -$704.76M S-4/A · filed 2026-09-03 |
| 2025-09-30 | -$691.77M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$684.02M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$674.64M 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$659.24M S-4/A · filed 2026-09-03 |
| 2024-09-30 | -$646.51M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$627.17M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$611.18M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$594.47M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$577.71M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$550.60M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$526.74M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$492.41M 10-K · filed 2024-03-04 |
| 2022-09-30 | -$465.33M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$438.63M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$399.09M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$356.28M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$305.13M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$258.21M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$209.78M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$170.90M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$131.95M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$103.42M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$76.25M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$58.66M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |